PARVULET
DEAD

Serial Number

78705641

Owner

Adare Pharmaceuticals, Inc.

Attorney

Dianne M. Lambillotte

Filing Date

Sep 1, 2005

Add to watchlist:

No watchlists yet
View on USPTO

PARVULET Trademark

Serial Number: 78705641 • Registration: 4215867

PARVULET is a trademark filed by Adare Pharmaceuticals, Inc. on September 1, 2005. The trademark is classified under Class 5 (Pharmaceuticals), Class 10 (Medical Apparatus), Class 40 (Treatment & Processing), Class 42 (Computer & Scientific). The application is currently no longer active.

Owner Contact Info

Adare Pharmaceuticals, Inc. (8 trademarks)

7722 Dungan Road
Philadelphia, PA 19111

Entity Type: 03

Egalet A/S (2 trademarks)

Lejrvej 39-41
Kirke Vaerlose, 3500 Vaerlose , DK

Entity Type: 99

Egalet Ltd. (5 trademarks)

160 Queen Victoria Street
London EC4V4QQ , GB

Entity Type: 03

Trademark Details

Filing Date

September 1, 2005

Registration Date

October 2, 2012

Published for Opposition

June 2, 2009

Cancellation Date

May 3, 2019

Goods & Services

Treatment of materials, namely, milling, mixing, grinding, liquefying, pulverizing, melting and extrusion of medical and pharmaceutical substances, compounds and materials

Pharmaceutical and veterinary preparations for the treatment of pain relief and pain management, shock, hemorrhage and bleeding, pre- and post-operative complications in the nature of hemorrhage, bleeding, thrombosis, emboli, stroke, apoplexy, lesions, respiratory and circulatory crises and dysfunctions, cognitive dysfunctions, fibrosis, infections, fever and sepsis, and traumas and emergencies, namely, fractures, abrasions, burns, psychological and immunological shock, poisons and pollutions, animal bites or stings, fever, respiratory and cardiovascular shock, crises and dysfunctions, and hemorrhage, bleeding, thrombosis, emboli, stroke, apoplexy, lesions and cognitive dysfunctions, and physical and psychological substance dependence, namely, drug and alcohol dependence, drug tolerance, withdrawal symptoms, convulsions, Alzheimer disease, dementias, Parkinson's disease, insufficient saliva and inability to swallow, allergy/immunology disorders, burns, diseases of the heart and blood vessels, dental and gum diseases, skin diseases, nutritional and dietary diseases, diseases of the endocrinological system and pancreatic diseases, diabetes, epidemical diseases in the nature of flu, AIDS/HIV, anthrax, plague, cholera, biological infections, and prion exposure, diseases and afflictions of the gastroenterological system, diseases of the blood, infectious diseases, neurological diseases, nephrological diseases, genitourinary diseases and afflictions, premature labor, poison exposure, cancer, ophthalmological diseases, diseases and afflictions affecting the bones, joints, cartilage material and muscles, diseases and afflictions of the ear, nose and throat, diseases and afflictions on the psychiatric field, pulmonological diseases and afflictions, rheumatism, urological diseases and afflictions, veterinary preparations for the treatment of bovine, sheep, horses, pigs, poultry, ostrich, rodents, dogs, cats, camels, donkeys, elephants; dietetic food adapted for medical use; diagnostic preparations for medical and veterinary use; drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals; synthetic peptides for pharmaceutical purposes; vitamins; biomedical compounds, namely, peptide substrates for use in analyzing and detecting toxins for medical laboratory use; pharmaceutical preparations, namely, a drug delivery system comprising polymer-based oral tablets, oral liquids, oral gels, and oral emulsions for the continuous release of a wide variety of therapeutic agents within a certain time after ingestion; medicated candy; medicated chewing gum; breath-freshening chewing gum for medical purposes; medicated lollipops; sweets for medicinal purposes, namely, sweets containing pharmaceutical and medical substances and compounds

Surgical, medical, dental and veterinary apparatus and instruments, namely, drug delivery apparatus and instruments in the form of containers for various pharmaceuticals, drugs, medicines, compounds and substances in the form of liquids, gels, grains, emulsions, blister packs and sachets; spoons, cups and syringes for administering pharmaceutical substances and medicines; drug delivery systems

Scientific research; technology consultation in the field of scientific research; design for others in the fields of pain relief and pain management, pharmaceutical drug and medicine development, development of medicines and medicine goods and packaging in the fields of traumas and emergencies, addictions, aging, allergy/immunology, burns, diseases of the heart and blood vessels, dental and gum diseases, skin diseases, nutritional and dietary diseases, diseases of the endocrinological system and pancreatic diseases, diabetes, epidemical diseases, diseases and afflictions of the gastroenterological system, diseases of the blood, infectious diseases, neurological diseases, nephrological diseases, diseases in the obstetrical- and gynecological field, occupational diseases and afflictions, cancer, ophthalmological diseases, diseases and afflictions affecting the bones, joints, cartilage material and muscles, diseases and afflictions of the ear-nose and throat, diseases and afflictions on the psychiatric field, pulmonological diseases and afflictions, rheumatism, urological diseases and afflictions, veterinary preparations for the treatment of bovine, sheep, horses, pigs, poultry, ostrich, rodents, dogs, cats, camels, donkeys, elephants; chemical, biochemical, biological and bacteriological research and analysis; pharmaceutical drug and medicine development services; design for others in the field of drugs and medicines; development of pharmaceutical preparations and medicines; professional consultancy pertaining to pharmacology, namely, biotechnical and biomedical and medical and pharmaceutical substances, preparations and compounds; professional consultancy in the field of research and development of medicine and the dispensing of pharmaceutical preparations; pharmaceutical drug development services comprised of scientific, industrial, technological, bio technical, pharmaceutical, biomedical and clinical research in the field of drugs and drug candidates; medical and scientific research, namely, conducting clinical trials of new drug candidates; consultation in the field of scientific research pertaining to chemical, pharmaceutical and medical goods; design for others in the field of medical packaging and equipment; development of pharmaceutical preparations and medicines; consultation in the field of biotechnological and biomedical scientific research; biochemical and molecular biological analyses; in vitro and in vivo preclinical tests and clinical tests of drug candidates and potential drugs; consultancy and research regarding pharmaceuticals in gel-like and viscous liquid dosage forms; consultancy and research pertaining to pharmacology in the nature of alternative drugs for the young, elderly and those with difficulties swallowing pills and tablets; development of in vitro and in vivo preclinical tests of drug candidates and potential drugs; biochemical and molecular biological analyses; scientific, industrial, technological and biotechnological analysis in the field of pharmaceutical and veterinary drug and medicine analysis, analysis of drug delivery apparatus and containers, analysis of synthetic peptides for pharmaceutical purposes, analysis of peptide substrates, analysis for the purpose of detecting various toxins, analysis of drug candidates and potential drugs

Filing History

AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
Jul 31, 2019 ASGN
CANCELLED SEC. 8 (6-YR)
May 3, 2019 C8..
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
Oct 2, 2017 REM1
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Sep 14, 2016 CHAN
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Sep 14, 2016 COAR
REGISTERED-PRINCIPAL REGISTER
Oct 2, 2012 R.PR
1(B) BASIS DELETED; PROCEED TO REGISTRATION
Aug 29, 2012 DP1B
NOTICE OF ALLOWANCE CANCELLED
Aug 15, 2012 IUCN
TEAS DELETE 1(B) BASIS RECEIVED
Aug 15, 2012 D1BR
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Feb 22, 2012 EXRA
SOU EXTENSION 5 GRANTED
Feb 21, 2012 EX5G
SOU EXTENSION 5 FILED
Feb 10, 2012 EXT5
SOU TEAS EXTENSION RECEIVED
Feb 10, 2012 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Aug 23, 2011 EXRA
SOU EXTENSION 4 GRANTED
Aug 20, 2011 EX4G
SOU EXTENSION 4 FILED
Aug 17, 2011 EXT4
SOU TEAS EXTENSION RECEIVED
Aug 17, 2011 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Feb 26, 2011 EXRA
SOU EXTENSION 3 GRANTED
Feb 25, 2011 EX3G
SOU EXTENSION 3 FILED
Feb 23, 2011 EXT3
SOU TEAS EXTENSION RECEIVED
Feb 23, 2011 EEXT
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
Oct 13, 2010 ASGN
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Sep 9, 2010 EXRA
SOU EXTENSION 2 GRANTED
Sep 8, 2010 EX2G
SOU EXTENSION 2 FILED
Aug 23, 2010 EXT2
SOU TEAS EXTENSION RECEIVED
Aug 23, 2010 EEXT
SOU EXTENSION 1 GRANTED
Jan 30, 2010 EX1G
CASE ASSIGNED TO INTENT TO USE PARALEGAL
Jan 29, 2010 AITU
SOU EXTENSION 1 FILED
Dec 21, 2009 EXT1
SOU TEAS EXTENSION RECEIVED
Dec 21, 2009 EEXT
NOA MAILED - SOU REQUIRED FROM APPLICANT
Aug 25, 2009 NOAM
PUBLISHED FOR OPPOSITION
Jun 2, 2009 PUBO
NOTICE OF PUBLICATION
May 13, 2009 NPUB
LAW OFFICE PUBLICATION REVIEW COMPLETED
Apr 28, 2009 PREV
APPROVED FOR PUB - PRINCIPAL REGISTER
Apr 27, 2009 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Apr 4, 2009 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Apr 4, 2009 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Apr 1, 2009 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Oct 8, 2008 GNRN
NON-FINAL ACTION E-MAILED
Oct 8, 2008 GNRT
NON-FINAL ACTION WRITTEN
Oct 8, 2008 CNRT
TEAS/EMAIL CORRESPONDENCE ENTERED
Sep 12, 2008 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Sep 12, 2008 CRFA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Sep 11, 2008 TCCA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Sep 11, 2008 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Mar 11, 2008 GNRN
NON-FINAL ACTION E-MAILED
Mar 11, 2008 GNRT
NON-FINAL ACTION WRITTEN
Mar 11, 2008 CNRT
TEAS/EMAIL CORRESPONDENCE ENTERED
Feb 6, 2008 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Feb 5, 2008 CRFA
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
Feb 5, 2008 ERSI
NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED
Nov 26, 2007 GNS2
INQUIRY TO SUSPENSION E-MAILED
Nov 26, 2007 GNSI
SUSPENSION INQUIRY WRITTEN
Nov 26, 2007 CNSI
SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
Nov 6, 2007 RCCK
REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
May 4, 2007 RCSC
ASSIGNED TO LIE
May 4, 2007 ALIE
LETTER OF SUSPENSION E-MAILED
Oct 25, 2006 GNSL
SUSPENSION LETTER WRITTEN
Oct 25, 2006 CNSL
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Oct 3, 2006 TCCA
TEAS/EMAIL CORRESPONDENCE ENTERED
Oct 3, 2006 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Oct 2, 2006 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Oct 2, 2006 TROA
NON-FINAL ACTION E-MAILED
Mar 30, 2006 GNRT
NON-FINAL ACTION WRITTEN
Mar 30, 2006 CNRT
ASSIGNED TO EXAMINER
Mar 16, 2006 DOCK
TEAS/EMAIL CORRESPONDENCE ENTERED
Feb 27, 2006 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Feb 15, 2006 CRFA
TEAS VOLUNTARY AMENDMENT RECEIVED
Feb 15, 2006 PARI
NEW APPLICATION ENTERED
Sep 9, 2005 NWAP